☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
In-Licenses
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA's Acceptance of IND for P-I Study of XL114 in...
October 15, 2021
Denovo In-Licenses Lundbeck's Idalopirdine for Alzheimer's Disease and Other Indications
July 2, 2021
Novartis In-Licenses Fibroblast Activation Protein (FAP) to Expand its Oncology Radioligand Pipeline
March 31, 2021
Novartis In-Licenses BieGene's Tislelizumab to Expand its Oncology Portfolio
January 12, 2021
Axsome In-Licenses Pfizer's Reboxetine and Esreboxetine in the US
January 14, 2020
Bausch Health In-Licenses Clearside's Xipere (triamcinolone acetonide suprachoroidal injectable suspension) For Macular Edema Asso...
October 24, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.